The FarmaBrasil group, which represents 12 of the main pharmaceutical companies in the
country, criticized the project that wants to extend the 20-year term of patents.
because the drug’s patent in Brazil ends in March this year. Pharmaceutical companies are interested in producing generics of the drug after registration ends.
The entity states that the project creates legal uncertainty for the sector and has immediate effects on prices and access. “Medicines with patents close to expiry would have a monopoly on sales, postponing competition from cheaper versions and putting pressure on public spending”, says the note.
PL 5810/2025 provides for the extension of the term of validity of patents when there is an allegation of administrative delay in the examination carried out by the INPI (National Institute of Industrial Property). The proposal has already been criticized by the vice-president of the republic, ().
The project has not yet passed through the committees, but the deputies obtained 362 votes, above the minimum necessary, to take the text directly to the plenary. Even so, it is far from consensus.
The final word will be from the President of the Chamber, (-PB). Motta’s allies say there is zero chance of planning the project right after the break. Many debates will still be held, say parliamentarians.
FarmaBrasil also claims that the proposal goes against the decision of the (Federal Supreme Court) that considered it unconstitutional to extend patent terms beyond the 20 years already provided for by law.
The group has also expressed its opposition to another project, . “The losers are the people who need guaranteed supply and expanded access,” said Reginaldo Arcuri, executive president of FarmaBrasil.
LINK PRESENT: Did you like this text? Subscribers can access seven free accesses from any link per day. Just click the blue F below.
